Oulu Mentalcare Oy

Futó vizsgálatok

• Toboroz

  NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

  NCT06963021· 3. fázis· Forrás

• Toboroz

  Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

  NCT06966401· 3. fázis· Forrás

• Fut, nem toboroz

  An Open-Label Study of Azetukalner in Major Depressive Disorder

  NCT06922110· 3. fázis· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Depresszió2 toboroz

Kutatók

Ide még nem kötődik kutató.

Lezárt vizsgálatok

• Lezárult

  A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and an Open- labeled Long-term Extension Treatment with Aticaprant

  2024-511557-21-00· 3. fázis· Forrás

• Lezárult

  Long-term Study to Assess the Safety and Effectiveness of NMRA-335140 in Participants with Major Depressive Disorder

  NCT06029439· 3. fázis· Forrás

• Lezárult

  Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder

  NCT06058039· 3. fázis· Forrás